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Abstract
 
The stroma of solid tumors is a complex network of different cell types. We analyzed stroma
cell interactions in two tumor models during cyclophosphamide (Cy)-induced tumor rejection.
In growing tumors, tumor infiltrating macrophages (TIMs) produced interleukin (IL)-10. Be-
ginning 6 h after Cy-treatment T cells in the tumor were inactivated and TIMs switched to in-
 
terferon (IFN)-
 

 
 production. Both, IL-10 production before and IFN-
 

 
 production after Cy-
treatment by TIMs required T cells. With the same kinetics as TIMs started to produce IFN-
 

 
the tumor vasculature was destroyed which required IFN-
 

 
 receptor expression on host but
not tumor cells. These events preceded hemorrhagic necrosis and residual tumor cell elimina-
tion by T cells. Together, T cells regulate the function of TIMs and tumor rejection can be in-
duced by disturbing the stroma network.
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
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Introduction
 
Tumor cells are usually embedded within a stroma which
sometimes constitutes a great part of the tumor tissue (1).
The tumor stroma is composed of a variety of normal cell
types (2) which at least in part appear to be actively re-
cruited by the tumor, e.g., to provide the blood supply (3).
Often, substantial numbers of T cells and macrophages are
part of the tumor stroma (4). Nevertheless, the tumor
grows progressively. The effectiveness of T cells to mediate
tumor rejection appears (at least in part) to depend on the
time of their activation. In previously immunized mice, T
cells can mediate rejection of a challenge tumor (5). In
contrast, when naive mice are inoculated with live tumor
cells or T cells are transfused to tumor-bearing animals, T
cells are activated but subsequently downregulated by the
growing tumor and become suppressive or anergic (6, 7).
 
North and Bursuker (8) showed that Ly-1
 

 
2
 

 
 effector cells
(CD8
 

 
 cytotoxic T lymphocytes) became activated shortly
after inoculation of tumor cells into naive recipients (be-
tween days 6 and 9), but then were downregulated by the
progressively growing tumor correlating with the appear-
ance of Ly-1
 

 
2
 

 
 (CD4
 

 
) suppressor T cells. That T cells
can suppress tumor rejection has been demonstrated, since
in some tumor models depletion of CD4
 

 
 T cells resulted
in rejection of established tumors (8–10). Nevertheless, the
nature of ‘suppressor’ T cells remains controversial, in par-
ticular because the mechanism by which they inhibited tu-
mor rejection is unresolved.
 
The role of tumor-infiltrating macrophages (TIMs)
 
*
 
 is
enigmatic. It has been proposed that, depending on the ac-
tivation state and the environment, they can regulate tumor
growth in a positive or negative fashion (4). For example,
tumors frequently express macrophage chemotactic factors
(11), macrophages can secrete angiogenic factors useful for
a growing tumor (12) and inhibition of macrophage infil-
tration correlated with the inability of the tumor to grow
 
in vivo (13). Conversely, artificial expression of macrophage
activating cytokines by tumor cells resulted in macrophage
infiltration and diminished tumor growth (14, 15). How-
ever, evidence of macrophage function in tumors is largely
indirect and a functional dynamics of TIMs during tumor
regression has not been shown.
Little is known of interactions between different stroma
cell components that either support tumor growth or are
involved in tumor rejection. We analyzed such interactions
and their alterations during rejection of established tumors.
For this purpose, we used cyclophosphamide (Cy) which
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Stroma Cell Interactions during Tumor Rejection
 
under certain experimental conditions can induce tumor
rejection by host cell modulation rather than direct tumor-
icidal activity (16–18). For example, a single injection of a
certain amount of Cy induced tumor rejection in immuno-
competent mice but had no effect on tumor growth in im-
munodeficient mice (19).
We used IFN-
 

 
 as a read-out for tumor stroma cell in-
teractions. A role of IFN-
 

 
 for tumor rejection has been
demonstrated (15, 20–23). Both IFN-
 

 

 
/
 

 
 and IFN-
 

 
 re-
ceptor (IFN-
 

 
R)
 

 
/
 

 
 mice are severely impaired to de-
velop systemic tumor immunity (21, 23). Additionally, he-
matopoietic and nonhematopoietic cells within the tumor
stroma appear to communicate via IFN-
 

 
 during tumor
rejection. By immunization/challenge experiments we
showed that CD4
 

 
 T cell–mediated tumor immunity re-
quired IFN-
 

 
R expression only on nonhematopoietic cells
in the effector phase and involved inhibition of angiogene-
sis (23). IFN-
 

 
 is produced mainly by activated T cells and
NK cells. Recently, it was shown that macrophages are
able to secrete large amounts of IFN-
 

 
 upon appropriate
stimulation (24). The IFN-
 

 
R is expressed on almost all
cell types (25, 26). Here we analyzed the dynamics of
stroma cell interactions in a growing tumor and during its
rejection. We show that during the phase of tumor estab-
lishment, T cells condition TIMs to produce IL-10. Upon
Cy-induced T cell inactivation TIMs immediately start to
produce IFN-
 

 
 and the tumor vasculature is destroyed in
an IFN-
 

 
R–dependent fashion.
 
Materials and Methods
 
Mice.
 
BALB/c mice were purchased from Charles River
Laboratories. Nude mice (BALB/c nu/nu) were obtained from
The Jackson Laboratory. IFN-
 

 
R 
 

 
-chain deficient (IFN-
 

 
R
 

 
/
 

 
)
mice generated as inbred 129/Sv/Ev line and congenic con-
trol 129/Sv/Ev mice were provided by M. Aguet, Epalinges,
Switzerland (27). Heterozygous offsprings generated by crossing
IFN-
 

 
R
 

 
/
 

 
 and 129/Sv/Ev mice were intercrossed to establish
IFN-
 

 
R
 

 
/
 

 
 and IFN-
 

 
R
 

 
/
 

 
 mice in the animal facility of the
Max-Delbrück-Centrum, Berlin, Germany. The deficiency of
the IFN-
 

 
R gene was confirmed by PCR of tail DNA as de-
scribed previously (27). All mice used in the experiments were
sex- and age-matched.
 
Tumor Growth and In Vivo Treatment.
 
The BALB/c plasma-
cytoma J558L and the 129/Sv/Ev fibrosarcoma Mc51.9, derived
from IFN-
 

 
R
 

 
/
 

 
 mice by treatment with 3-methylcholanthrene
(23) were cultured in RPMI 1640 medium supplemented with
10% FCS. For tumor establishment, 10
 
6
 
 J558L cells, 2 
 

 
 10
 
5
 
 or
10
 
6
 
 Mc51.9 cells were washed twice with PBS and subcutane-
ously injected in a volume of 0.2 ml into the flank of mice as in-
dicated. On days 11 or 15 when J558L or Mc51.9 tumors were
established, a single dose of 15 mg/kg (BALB/c) or 50 mg/kg
(129/Sv/Ev) Cy in Dulbecco’s PBS (Sigma-Aldrich) was admin-
istered intraperitoneally. Tumor size was measured by a caliper
and determined as the mean of the largest diameter and the diam-
eter at right angle. J558L tumors had an average size of 1 cm in
diameter 11 d after injection. To estimate the tumor volume
J558L tumors of 1 cm in diameter were isolated and the weight
was determined as 630 
 

 
 10 mg. Tumor rejection was defined as
complete regression after treatment and the absence of recurrent
 
tumor for the entire follow-up period (at least 60 d). For in vivo
depletion of T cell subsets, tumor-bearing BALB/c mice were
depleted of T cell subsets by intraperitoneal injection of 100 
 

 
g
rat mAb GK1.5 (anti-CD4) or 2.43 (anti-CD8) in a volume of
0.5 ml, 2 d before tumor cell inoculation and/or 2 d before Cy
injection. Depletion of the respective T cell subpopulation was
controlled by flow cytometric analysis of peripheral blood cells
using PE-labeled anti-CD4 (RM4–5) and anti-CD8 mAbs (53–
6.7) (BD PharMingen) and lasted for at least 4 wk.
 
Cytokine Detection.
 
Mc51.9 tumors were established by sub-
cutaneous injection of 2 
 

 
 10
 
5
 
 cells into 129/Sv/Ev (IFN-
 

 
R
 

 
/
 

 
)
and nude mice. 11 d later, mice were treated with 50 mg/kg
Cy. Before, 6 h, 24 h, and 72 h after treatment spleen and
tumors were excised. Splenocytes (three mice per group) were
cultured at 10
 
6
 
 cells per milliliter in a 24-well plate without stim-
ulant, with 10 
 

 
g/ml anti-CD3 mAb (37.51), and 5 
 

 
g/ml anti-
CD28 mAb (145–2C11; BD PharMingen) or with 1 
 

 
g/ml
ConA (Sigma-Aldrich) for 24–48h. Single cell suspensions of tu-
mors (3–5 mice per group) were prepared by mechanical dissoci-
ation and collagenase/DNase I treatment for 45–60 min at 37
 
	
 
C
(1 mg/ml collagenase, 1
 

 
 trypsin/EDTA; GIBCO BRL; 1 mg/
ml Dnase I; Boehringer). The cells were then plated in medium
at 4 
 

 
 10
 
5
 
 cells per milliliter in a 24-well plate and incubated at
37
 
	
 
C for 2 h. Nonadherent tumor infiltrating cells were col-
lected and cultured at 10
 
6
 
 cells per milliliter with or without
stimulation as described for spleen cells. T cell numbers in tu-
mors did not differ significantly before and within the first 3 d af-
ter Cy-treatment. For separation of macrophages, cell suspen-
sions were incubated with microbeads coupled anti–Mac-1
(CD11b) (Miltenyi Biotec) and passed over a MACS
 
®
 
 column
according to the manufacturer’s recommendation. The purity of
macrophage preparations was between 71 and 93% as deter-
mined by cell morphology, plastic adherence, and flow cytomet-
ric analysis (data not shown). Mac-1
 

 
 cells were plated in me-
dium at 10
 
6
 
 cells per milliliter in a 24-well plate and cultured
with or without 1 
 

 
g/ml LPS for 24 h. IFN-
 

 
 or IL-10 in the
culture supernatant was determined by ELISA (BD PharMin-
gen). The detection limit was between 31 and 62 pg/ml for both
cytokines. Mc51.9 cells did not secrete IL-10 or IFN-
 

 
, either
spontaneously or after LPS stimulation (data not shown). The T
cell–regulated IFN-
 

 
 production by TIMs was also analyzed in a
second tumor model. J558L tumors were established by subcuta-
neous injection of 10
 
6
 
 cells into BALB/c mice. 11 d later, mice
were left untreated or treated with 15 mg/kg Cy. The mice (3–
5/group) were additionally depleted of CD4
 

 
/CD8
 

 
 T cells
starting either before tumor cell inoculation (day –2 and day 9)
or before Cy application (day 9) by use of mAb GK1.5 (anti-
CD4) and 2.43 (anti-CD8) as described previously. One group
of mice was not depleted of T cells. TIMs were isolated on day
12 from not Cy-treated mice or 24 h after Cy-treatment and
cultured as above without stimulation or stimulated with IL-12
(10 ng/ml) and IL-18 (10 ng/ml). Mac-1
 

 
 cells isolated via
MACS
 
®
 
 had a purity of 
 

 
90%. After 48-h incubation, culture
supernatant was collected and IFN-
 

 
 was determined as de-
scribed previously.
 
Flow Cytometric Analysis.
 
Tumors were established by subcu-
taneous injection of 2 
 

 
 10
 
5
 
 Mc51.9 cells into IFN-
 

 
R
 

 
/
 

 
 and
nude mice. 11 d later, single cell suspension of tumors (3–5 mice
per group) was prepared as described previously. Cells were di-
rectly stained using PE-labeled anti–Mac-1 mAb (M1/70; BD
PharMingen) and analyzed with an Epics-XL flow cytometer
(Coulter Electronics). Mc51.9 cells did not express detectable
Mac-1 (data not shown).
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Immunohistochemical Analysis.
 
Isolation of tumor tissues, prep-
aration of cryostat sections, and alkaline phosphatase immu-
nostaining were done as described previously (14). 2 
 

 
 10
 
5
 
Mc51.9 cells were injected subcutaneously into IFN-
 

 
R
 

 
/
 

 
 and
IFN-
 

 
R
 

 
/
 

 
 or nude mice. 11 d later, mice were treated with 50
mg/kg Cy. Tumors were excised before, 6 h, 24 h, and 72 h after
treatment. For detection of TIMs consecutive sections were
stained with anti-F4/80 (cl: A3–1; Serotec). Endothelial cells
were identified with Meca 32 (28) or anti-CD31 mAb (MEC
13.3; BD PharMingen). The alkaline phosphatase-conjugated
goat anti–rat IgG was purchased from Jackson ImmunoResearch
Laboratories. All sections were then counterstained with Mayer’s
hematoxylin (Chroma Gesellschaft GmbH, Münster, Germany).
Tissue sections of 3–4 mice per group were evaluated.
 
Results
 
T Cell-dependent and -independent Phases during Cy-induced
Tumor Rejection.
 
We employed a model in which rejec-
tion of established solid tumors was induced by a treatment
which did not act directly on the tumor cells. Nude and
BALB/c mice bearing J558L tumors of a size of 
 

 
1 cm in
diameter were treated with a single injection of Cy (15
mg/kg). Whereas tumors in nude mice progressively grew
without any retardation, tumors in BALB/c mice became
severely necrotic after 
 

 
3 d and finally were rejected
within 10–20 d (Fig. 1). This experiment showed that Cy,
at the applied dose, had no significant direct effect on the
tumor cells and that tumor necrosis and subsequent rejec-
tion was T cell dependent. The involvement of T cells is
further indicated by the observation that BALB/c mice
which rejected the J558L tumor upon Cy-treatment re-
jected a second challenge of J558L but not unrelated tumor
cells (data not shown).
To elucidate the contribution of T cells for tumor ne-
crosis or rejection and the time point of their requirement,
CD4
 

 
, CD8
 

 
, or both T cell subsets were depleted in tu-
mor-bearing mice before Cy-injection. Cy administration
induced tumor necrosis in CD4
 

 
, CD8
 

 
, and surprisingly
also in CD4
 

 
/CD8
 

 
 T cell–depleted animals (Table I).
Similar as observed in nude mice, Cy did not induce tumor
necrosis in BALB/c mice depleted of CD4
 
/CD8 T cells
before tumor inoculation (Table I), indicating that T cells
were necessary during tumor establishment but not during
Cy-treatment for tumor necrosis. However, complete tu-
mor rejection was found only in CD4 but not in CD8
or CD4/CD8 T cell–depleted mice. After a short period
of time tumors in CD8 T cell–depleted mice started to
grow again by forming a ring-like structure around the ne-
crotic area (Fig. 1 e). Of note, some mice (2/10) rejected
the tumor after CD4 T cell depletion without Cy-treat-
ment, indicating partially overlapping effects induced by
Cy and CD4 T cell depletion (see below).
Cy-mediated Tumor Rejection Requires IFN-R Expression
by Host but not Tumor Cells. IFN- has been associated in
several studies with tumor rejection (15, 20–23). We asked
whether it was necessary for Cy-mediated tumor rejection.
To confirm the Cy-effect in a second tumor model and to
distinguish whether a possible contribution of IFN- in-
volved its activity on tumor or host cells, we used the fib-
rosarcoma Mc51.9, derived from a 129/Sv/Ev IFN-R/
mouse. Mc51.9 cells were injected into IFN-R/ and
IFN-R/ mice. After 11 d when tumors were estab-
Figure 1. T cell involvement during Cy-mediated tumor rejection. (a)
Tumors were established by subcutaneous injection of 106 J558L cells into
BALB/c and nude mice. 11 d later, when tumor reached a size of 1 cm in
diameter, BALB/c (, n 
 10) and nude mice (, n 
 10) were treated
intraperitoneally with 15 mg/kg Cy. BALB/c (, n 
 10) and nude mice
(, n 
 10) which had not received Cy treatment served as controls. All
Cy-treated BALB/c mice rejected the tumor, whereas all mice from the
other groups did not. SD did not exceed 10% in all cases. Data are represen-
tative for three independent experiments. (b–d) An example of a tumor be-
fore (b), three (c), and 10 d after Cy-treatment (d). (e) Tumor 10 d after Cy
treatment in mice depleted of CD8 T cells (see Table I). The arrow indi-
cates the ring-like structure of the growing tumor around the necrotic area.
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lished, mice were treated with Cy. All IFN-R/ mice
rejected the tumors, whereas they continued to grow with-
out Cy-treatment (Fig. 2 a). In contrast, tumors in IFN-
R/ mice were not rejected after treatment. Because
Mc51.9 tumors grew slightly faster in IFN-R/ com-
pared with IFN-R/ mice, IFN-R/ and IFN-R/
mice were also treated with Cy when Mc51.9 tumors
had grown to a similar size (Fig. 2 b). Again, Cy-treatment
Table I. T Cell-dependent and -independent Phases during Cy-induced Tumor Necrosis/Rejection
T cell depletion Cy treatment Tumor necrosisa Rejection (No./Total)b
Subset Time
None  0/5 0/5
 10/10 10/10
CD4 day 9  2/10 2/10
 5/5 5/5
CD8 day 9  0/5 0/5
 10/10 0/10
CD4, CD8 day 9  0/3 0/3
 7/7 0/7
CD4, CD8 days 2 and 9  0/3 0/3
 0/3 0/3
BALB/c mice were inoculated subcutaneously with 106 J558L cells. 11 d later, when tumors reached a size of 1 cm in diameter, mice were treated
with 15 mg/kg Cy. 2 d prior to Cy-administration or tumor cell injection mice were depleted of CD4 and/or CD8 T cells. Untreated mice served
as control.
aTumor necrosis was observed on days 3–5 after treatment.
bMice were observed for 60 d.
Figure 2. Cy-mediated tumor rejection requires IFN-R expression on host
but not tumor cells. (a) IFN-R/ (, n 
 10) and IFN-R/ 129/Sv/Ev
mice (, n 
 10) were injected subcutaneously with 2  105 Mc51.9 cells (de-
rived from an IFN-R/ mouse) and 11 d later treated intraperitoneally with
50 mg/kg Cy. IFN-R/ (, n 
 5) and IFN-R/ mice (, n 
 5) which
did not receive Cy treatment served as controls. Data are representative for two
independent experiments. (b) IFN-R/ mice (, n 
 5) were injected subcu-
taneously with 2  105 and IFN-R/ mice (, n 
 5) with 106 Mc51.9 cells.
11 (for IFN-R/ mice) and 15 d (for IFN-R/ mice) later, respectively,
when tumors reached a size of 1 cm in diameter, mice were treated intraperito-
neally with 50 mg/kg Cy. Untreated tumor bearing IFN-R/ (, n 
 5) and
IFN-R/ (, n 
 5) mice served as controls. All Cy-treated IFN-R/ mice
rejected the tumor, whereas all mice from the other groups did not. SD did not
exceed 10% in all cases.
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of IFN-R/ mice resulted in complete tumor rejection,
whereas tumors in IFN-R/ mice continued to grow
with a short retardation. These data show that Cy-induced
tumor rejection depends on IFN-R expression, yet only
by host and not tumor cells.
Cy-Treatment Rapidly Inactivates Tumor-infiltrating T Cells.
Because of the requirement of IFN-R for Cy-mediated
tumor rejection we analyzed the ability of tumor-infiltrat-
ing T cells (TILs) to produce IFN- after Cy-treatment.
11-d-old Mc51.9 tumors contained CD4 and CD8 T
cells as determined by flow cytometry and immunohis-
tochemistry (data not shown). Nonadherent infiltrating
cells of tumors grown in 129/Sv/Ev mice were isolated be-
fore, 6, 24, and 72 h after Cy-treatment of the mice, stimu-
lated in vitro with CD3/CD28 mAb and IFN- pro-
duction was measured. Without stimulation the cells
produced either very little or no IFN- (Fig. 3). CD3/
CD28 mAb-stimulation of tumor-infiltrating cells isolated
before Cy-treatment led to the production of large
amounts of IFN-. Starting 6 h after Cy-treatment IFN-
production was dramatically reduced and after 72 h the
cells had completely lost the ability to produce IFN-.
Spleen cells isolated from tumor-bearing mice at the differ-
ent time points after Cy-treatment showed little changes in
IFN- production upon CD3/CD28 mAb-stimulation
(Fig. 3). Similar results were obtained after ConA stimula-
tion (data not shown). Therefore, we conclude that TILs
are functionally inhibited rapidly after Cy-treatment and
are unlikely the source of IFN- necessary for Cy-medi-
ated tumor rejection. This is compatible with the observa-
tion that T cells are not necessary early after Cy-treatment
for tumor necrosis. Additionally, in the early phase of tu-
mor rejection the most pronounced effect of Cy was locally
on the TILs even though systemic effects cannot be ex-
cluded.
Cy-treatment Switches Cytokine Production of TIMs from IL-
10 to IFN-. To search for an alternative source of IFN-
after Cy-treatment we analyzed cytokine production of
TIMs before and after Cy-treatment of Mc51.9 tumor-
bearing mice. At the time of Cy-treatment (11 d after tu-
mor cell injection) tumors were infiltrated by substantial
numbers of macrophages as judged by immunohistochemi-
cal and flow cytometric analysis with F4/80 and -Mac1
(CD11b) mAbs, respectively (Fig. 4 a and c), and by mor-
phology and plastic adherence upon isolation. Macrophages
isolated from tumors before Cy-treatment spontaneously
produced IL-10 that increased by stimulation with LPS
(Fig. 4 e). TIMs isolated 6 and 24 h after Cy-treatment did
not produce IL-10 and little IL-10 was detected 72 h after
Cy-treatment. Conversely, TIMs isolated before Cy-treat-
ment did not produce IFN- but within 6 h after treatment
started to produce IFN- that gradually increased after 24
and 72 h (Fig. 4 e). Similar results were obtained when
macrophages were stimulated with LPS. These results show
rapid and profound effects of Cy-application on TIMs.
Cy-induced IFN- Production by TIMs Is T Cell Depen-
dent. Since the induction of tumor necrosis required the
presence of T cells before Cy-treatment, we asked whether
IFN- production by macrophages was T cell dependent.
Macrophages infiltrated Mc51.9 tumors in nude mice (Fig.
4 b and d) to a similar extent as those in T cell–competent
mice (Fig. 4 a and c) indicating that they infiltrated the tu-
Figure 3. Rapid functional inactivation of TILs but not spleen cells after Cy-treatment. 129/Sv/Ev (IFN-R/) mice were inoculated subcutane-
ously with 2  105 Mc51.9 cells and 11 d later intraperitoneally injected with 50 mg/kg Cy. Before, 6 h, 24 h, and 72 h after Cy treatment tumors (3–5
mice per group) and spleens (three mice per group) were excised. Single cell suspensions of tumors were prepared and nonadherent cells were cultured
at 106 cells per milliliter without or with stimulation by -CD3/-CD28 mAb’s for 24 h. Spleen cells (106 cells per milliliter) were cultured without or
with -CD3/-CD28 mAb stimulation for 48 h. IFN- in the culture supernatants was determined by ELISA. Data are representative for two inde-
pendent experiments.
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mor largely in a T cell–independent fashion. Macrophages
isolated from tumors grown in nude mice produced very
little or no IL-10 before Cy-application and LPS was un-
able to enhance the IL-10 production (Fig. 4 f). Remark-
ably, macrophages isolated from tumors in nude mice did
not produce IFN- either before or at any time point after
Cy-treatment (Fig. 4 f). Thus, Cy-induced IFN- produc-
tion by macrophages required the presence of T cells.
T Cells Prevent IFN- Production by TIMs in Growing Tu-
mors. The correlation between functional inhibition of
TILs and IFN- production of TIMs raised the question
whether T cells, although necessary for IFN- production
by TIMs upon Cy-treatment, were also responsible for the
failure of TIMs to do so in growing tumors. TIMs were
isolated from J558L tumors grown in BALB/c mice before
or 24 h after Cy-treatment. Three groups of mice were an-
alyzed: mice that were not depleted, depleted of CD4/
CD8 T cells starting before tumor cell injection, or before
Cy-treatment (Fig. 5). TIMs isolated from nonT cell–
depleted mice did not produce IFN- without Cy-treat-
ment, however in treated mice they produced IFN- simi-
lar as observed in the MC51.9 tumor model. TIMs isolated
from tumors of mice depleted of T cells throughout the ex-
periment did not produce IFN- regardless of Cy-treat-
ment. This confirms that Cy-induced IFN- production
by TIMs requires the presence of T cells during the period
between tumor cell injection and Cy-treatment.
Remarkably, T cell depletion in tumor-bearing mice in-
duced IFN- production by TIMs even without Cy-treat-
ment. In parallel, TIMs of all experimental groups were in
vitro stimulated with IL-12 and IL-18, a strong stimulus for
macrophages to produce IFN- (24). TIMs of all groups
had the ability to produce large amounts of IFN-. The
amount was proportional to that seen without in vitro
stimulation (Fig. 5). Collectively, these data demonstrate
that in the early phase TIMs require T cells to acquire the
Figure 4. Cy treatment switches T cell–dependent cytokine production of TIMs from IL-10 to IFN-. (a–d) IFN-R/ 129/Sv/Ev (left) and nude
mice (right) were inoculated subcutaneously with 2  105 Mc51.9 cells. 11 d later, tumors were obtained and macrophages were identified by immuno-
histology with -F4/80 mAb (a and b) and flow cytometry with –Mac-1 (CD11b) mAb (c and d). (e) IFN-R/ 129/Sv/Ev and (f) nude mice were
inoculated with tumor cells as above and 11 d later injected intraperitoneally with 50 mg/kg Cy. Before, 6 h, 24 h, and 72 h after Cy treatment single cell
suspension of tumors (3–5 mice per group) were prepared, Mac-1 cells were isolated and cultured at 106 cells per milliliter without or with stimulation
by 1 g/ml LPS for 24 h. IFN- and IL-10 in the culture supernatants were determined by ELISA. One of two experiments with similar results is shown.
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ability to produce IFN-, while in the later phase T cells
inhibited IFN- production by TIMs.
Cy Induces IFN-R–mediated Destruction of the Tumor Vas-
culature. Finally, we searched for the target of IFN-
during Cy-induced tumor rejection. Because we had pre-
viously shown that CD4 T cell–mediated tumor immu-
nity involved inhibition of angiogenesis which required
IFN-R expression on nonhematopoetic cells, most likely
in the tumor stroma, and because of the rapid hemor-
rhagic necrosis after Cy treatment, we analyzed the tumor
vasculature after Cy treatment. IFN-R/ and IFN-
R/ mice bearing established Mc51.9 tumors were
treated with Cy. Tumors were isolated before and af-
ter treatment and cryosections were stained with mAb
-Meca 32, which recognizes an epitope constitutively ex-
pressed on vascular endothelia (28). A dense net of blood
vessels was visible in tumors of IFN-R/ and IFN-
R/ mice before treatment (Fig. 6 a and f). Cy treat-
ment of IFN-R/ mice resulted in a significant decrease
in the number of blood vessels, as early as 6 h after treat-
ment. After 24 h a further reduction of vessel density was
observed and after 72 h blood vessels in the tumor were
almost undetectable (Fig. 6 b–d). Importantly, blood vessel
destruction preceded significant necrosis in the tumor tis-
sue. Cy treatment of IFN-R/ mice did not induce any
decrease in tumor blood vessel density compared with un-
treated tumors (Fig. 6 g–i). Instead, a continuous increase
in blood vessel density could be observed in tumors of
treated and control IFN-R/ mice. These results were
confirmed by using a second mAb, -CD31 (platelet/en-
dothelial cell adhesion molecule-1), directed against endo-
thelial intracellular junctions (Fig. 6 e and j). Thus, Cy
rapidly induces the destruction of the tumor vasculature in
an IFN-R–dependent fashion.
Discussion
We analyzed the time-course of tumor stroma cell inter-
actions during rejection of established tumors. It is known
that a single injection of a certain amount of Cy can induce
rejection of some established solid tumors (17, 18). Several
findings already indicated that tumor rejection by Cy can
be the result of host cell modulation rather than direct tu-
moricidal activity: (i) Cy-induced tumor rejection was T
cell dependent (19); (ii) low dose was more effective than
high dose treatment (29); (iii) the time interval between tu-
mor inoculation and Cy administration rather than the tu-
mor size was critical for tumor rejection (30); and (iv) Cy-
mediated tumor rejection was inhibited, if mice had been
treated earlier with Cy (29). An indirect mode of action
was confirmed here, since Cy, at the given doses, had no
obvious effect on tumors growing in nude mice or normal
mice which were depleted of T cells from the time of tu-
mor cell inoculation. Based on the results presented here
we distinguish three phases during Cy-induced tumor re-
jection: (i) the time between tumor cell inoculation and
Cy-application; (ii) the early phase after Cy-treatment de-
fined by hemorrhagic necrosis and; (iii) the late phase de-
fined by elimination of residual tumor cells which survived
hemorrhagic necrosis at the rim of the tumor.
The first phase (tumor establishment) is characterized by
the accumulation of different host-derived stroma cells,
e.g., inflammatory cells such as T cells and macrophages or
cells involved in the establishment of the tumor vascula-
Figure 5. T cells prevent IFN- production by TIMs in growing tumors. BALB/c mice were subcutaneously inoculated with 106 J558L cells and 11 d
later intraperitoneally injected with 15 mg/kg Cy. Additionally, mice were depleted of CD4/CD8 T cells starting before tumor cell injection, before
Cy-treatment, or as control not depleted of T cells. Before and 24 h after Cy-treatment single cell suspensions of tumors (3–5 mice per group) were pre-
pared, Mac-1 cells were isolated and cultured at 106 cells per milliliter without or with stimulation by IL-12 and IL-18 for 24 h. IFN- in the culture
supernatant was determined.
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ture. The inflammatory response to the tumor is slow in
comparison to that observed in previously immunized mice
(23) and, in contrast to preimmunized mice, the tumor
continues to grow. Critical for a tumor permissive environ-
ment appeared to be the interaction between macrophages
and T cells. Macrophages infiltrated the tumor to a large
extent in a T cell–independent manner, yet their IL-10
production before and IFN- production after Cy-treat-
ment required the presence of T cells. Therefore, it is likely
that macrophages interacted with T cells within the tumor.
The role of T cells during the tumor establishment phase is
complex. On the one hand macrophages need T cells to
obtain the ability to produce IFN-, on the other hand T
cells prevent macrophages to not produce IFN-. It has to
be shown whether the T cells themselves are regulated by
the tumor similar as demonstrated in other tumor models
which showed activation and subsequent conversion of T
cells by the growing tumor (7, 8).
Figure 6. Cy induces IFN-R–dependent
destruction of the tumor vasculature. Tu-
mors were established in IFN-R/ and
IFN-R/ 129/Sv/Ev mice by subcutane-
ous injection of 2  105 Mc51.9 cells. 11 d
later, mice were injected intraperitoneally
with 50 mg/kg Cy and tumors were excised
before, 6 h, 24 h, and 72 h after Cy treat-
ment. Immunohistochemical analysis of tis-
sue sections from IFN-R/ mice (a–e) and
IFN-R/ mice (f–j) was performed with
mAb Meca 32 (a-d, f–i) or with mAb anti-
CD31 (e and j). Original magnification:
100. A representative staining of tumors
from 3–4 mice per group is shown.
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A suppressive nature of T cells in the established tumor is
indirectly indicated by T cell–dependent IL-10 production
of TIMs. It has been shown that IL-10 acts immunsuppres-
sive, e.g., downmodulates T cell function (31), inhibits the
accumulation of dendritic cells in the tumor (32) or down-
regulates MHC class I expression on tumor cells (33, 34).
However, direct evidence for the suppressive activity of T
cells and the mode of suppression was demonstrated by
their inactivation and the immediate changes within the tu-
mor environment. Similar as shown before (9, 10), CD4
T cell depletion induced rejection of J558L tumors in some
of the mice (2/10). Furthermore, Cy-treatment rapidly in-
activated TILs, as shown by their inability to produce IFN-.
Thus, TILs are unlikely the source of IFN- necessary
for Cy-mediated tumor necrosis. This is consistent with
the observation that CD4/CD8 T cell depletion at the
time of Cy-treatment still led to tumor necrosis. However,
we cannot exclude that IFN- produced by T cells con-
tributes to tumor vasculature destruction. The fact that the
TILs could be induced in vitro to produce IFN- when
isolated before Cy-treatment does not mean that they in
fact produced IFN- in situ. Rather, their inability to pro-
duce IFN- after Cy-treatment could reflect the inability
to produce other unknown factors that regulate macro-
phage function. With the same kinetics as TILs were inac-
tivated by Cy, TIMs stopped to produce IL-10 and started
to produce IFN-. Sica et al. recently showed that macro-
phages from mouse and human tumors produced IL-10
that inhibited IL-12 production in an autocrine manner
(35). Because macrophages can be induced to produce
IFN- by IL-12 and IL-18 (24), it is possible that these cy-
tokines produced by macrophages themselves or other cells
within the tumor stroma contributed to Cy-mediated tu-
mor rejection. Recently, it has been shown that IL-12 can
support Cy-mediated tumor rejection (36). In any case,
IFN- most likely produced by macrophages was of pivotal
importance, since Cy did not induce tumor rejection in
IFN-R/ mice. Cy caused a short delay of tumor
growth in IFN-R/ mice that we cannot explain at the
present time but could be due to other factors induced by
Cy. To exclude that Cy directly induced the functional
switch of TIMs, we showed that T cell depletion led to
IFN- production by TIMs similar as Cy-treatment. This
shows that the TIMs were directly suppressed by T cells
and that Cy-treatment and T cell depletion induced at least
partially overlapping effects. Since (CD4) T cell depletion
did not or only rarely induce tumor rejection compared
with Cy-treatment, yet both treatments let to IFN- pro-
duction by TIMs, IFN- may be a necessary but not suffi-
cient factor. Collectively, the results suggest that one factor
determining a permissive tumor environment is ‘holding in
check’ the TIMs by T cells whose suppressive/regulatory
phenotype may be caused by their too late arrival in the
tumor.
The tumor cells did not need to express IFN-R for
Cy-induced tumor rejection. Which host cells have to ex-
press the IFN-R is not entirely clear. Previously we
showed that tumor immunity mediated by CD4 T cells
against the MHC class II Mc51.9 tumor involves inhibi-
tion of angiogenesis which required IFN-R expression by
nonhematopoietic cells, most likely within the tumor
stroma (23). Therefore, we assume that IFN- has a similar
cellular target during Cy-induced tumor rejection. The
most striking effect of Cy was the destruction of the tumor
vasculature in IFN-R/ but not IFN-R/ mice
which preceded tumor necrosis and occurred with similar
kinetics as TILs were inactivated and TIMs started to pro-
duce IFN-. A possible target of IFN- are endothelial
cells themselves, supported by the demonstration that IFN-
(together with TNF) impairs survival of endothelial cells
in vitro (37). Alternatively, other cells of the tumor stroma
such as fibroblasts could be the target of IFN- and be in-
volved in blood vessel destruction by release of other fac-
tors (38, 39). It should be noted that TILs from IFN-R/
mice could be induced to produce IFN- before and lost
the ability after Cy-treatment similar to those isolated from
IFN-R/ mice. Also, TIMs from IFN-R/ mice
switched from IL-10 to IFN- production during Cy-
treatment (data not shown). Compatible with a xenograft
model of arteriosclerosis (40), IFN- seems to have an ef-
fector rather than regulatory role during Cy-induced tumor
rejection. Different from our results it was recently sug-
gested that Cy directly affected tumor angiogenesis (41). In
this study Cy was repeatedly applied in high amounts (170
mg/kg). We can exclude direct effect of Cy in our model,
since the tumor vasculature appeared to be unaffected in
IFN-R/ mice.
After destruction of the tumor vasculature the tumor be-
comes centrally necrotic. In the J558L tumor model few
cells at the periphery of the tumor appear to survive and
they are eventually eliminated by CD8 T cells. We did
not analyze T cell subset requirement in the Mc51.9 tumor
model where CD4 T cells are essential effector cells in
immunization/challenge experiments (23). The CD8 T
cells necessary for elimination of residual J558L cells could
either be liberated from a suppressive activity of CD4 T
cells abolished by Cy (9) or, alternatively, induced as a re-
sult of high amounts of antigens available for APCs (e.g.,
the activated macrophages in the tumor) during tumor ne-
crosis. Further Cy-treatment during this period might im-
pair residual tumor cell elimination by T cells which upon
activation can be assumed to proliferate, and thus should be
more susceptible to Cy-toxicity.
Several approaches have been developed to induce inhi-
bition of tumor angiogenesis (3, 42) or tumor infarction
(43). Cy is particularly interesting because for no currently
used antiangiogenic compound more clinical data exist.
Whether some of the therapeutic or toxic effects in the
clinic can be explained by Cy-induced vascular damage and
whether they are immune-mediated is currently not
known. The rapid kinetics of Cy-induced alterations
within the tumor stroma, however, would be difficult to
reconcile with the supposed effect of Cy to act on rapidly
dividing cells. In summary, the importance of stroma for
protection of solid tumors, e.g., as barrier for infiltrating
immune cells has been recognized (44, 45). We have
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shown here that the rejection of some transplanted tumors
can be induced by altering the balance between individual
components of the tumor stroma.
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